Abstract 2688: Establishment of high avidity CTL clones induced by HLA-A2 restricted glypican-3 (GPC3) peptide vaccine
Toshiaki Yoshikawa(Aichi Cancer Center), Tetsuya Nakatsura(Unknown), Noriko Sakemura(National Cancer Center Hospital East), Shiro Suzuki(National Cancer Center Hospital East), Hirofumi Shirakawa(Shizuoka Cancer Center), Yutaka Motomura(Shizuoka Cancer Center), Munehide Nakatsugawa(Tokyo Medical University Hachioji Medical Center), Daisuke Nobuoka(Fukuyama City Hospital)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104